Current filters:


Popular Filters

6651 to 6675 of 6816 results

Pfizer Ph II study confirms efficacy of Ablynx' ozoralizumab in RA


Belgian drug developer Ablynx (Euronext Brussels: ABLX) revealed top-line results from the recently…


Roche and Evotec terminate Ph II study with NR2B in treatment-resistant depression


German biotech firm Evotec AG (Xetra: EVT) and Swiss drug major Roche (SIX: ROG) say they have decided…


Pharma distribution in Central Europe in 2011: liberalization of non-pharmacy and on-line sales


Pharmaceutical distribution has been liberalized further in Central Europe in 2011, with Bulgaria making…

EuropeMarkets & MarketingPharmaceuticalRegulation

Roundup of upcoming cancer drug trials to be presented at ASCO


A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have…


FDA advisory panel backs continued use of Abbott’s Trilipix with statins


The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review…

Abbott LaboratoriesCardio-vascularNorth AmericaPharmaceuticalRegulationTrilipix

Record $3 billion disbursed in 2010 by Global Fund to Fight AIDS


The Global Fund to Fight AIDS, Tuberculosis and Malaria disbursed a record $3 billion in 2010. This helped…

Anti-viralsFinancialGlobalHealthcarePharmaceuticalTropical diseases

10% of US cancer patients abandoned oral drug therapy, often on cost grounds


In the USA, 10% of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs,…

HealthcareNorth AmericaOncologyPharmaceuticalPricing

Nycomed agrees to 9.6 billion euros takeover by Takeda


Despite just yesterday again saying that it "has not agreed to any such an agreement," this morning Takeda…

Mergers & AcquisitionsNycomedPharmaceuticalTakeda Pharmaceuticals

Global pharma market will see just 3%-6% growth over next five years, reaching $1,100 billion in 2015


Global spending for medicines will reach nearly $1,100 billion by 2015, reflecting a slowing compound…

GenericsGlobalMarkets & MarketingPatentsPharmaceutical

Astellas’ mirabegron improves key OAB symptoms in Ph III study


The US subsidiary of Japanese drug major Astellas (TSE: 4503) says that the results of a pivotal Phase…

Astellas PharmaGastro-intestinalsmirabegronPharmaceuticalResearch

Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market


US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator…

AriceptEisaiNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Amgen says Xgeva first drug to prevent spread of bone cancer in prostate cancer patients


Amgen (Nasdaq: AMGN), the world’s largest biotech company, has announced primary results of a pivotal…


Eisai gets Swiss approval for Halaven


Japanese drug major Eisai (TYO: 4532), says that its Halaven(eribulin) has been approved for use in…


Satisfaction with gastric cancer treatment options remains low, GfK study notes


In just over a month following the US Food and Drug Administration’s approval last fall of Swiss…

HerceptinMarkets & MarketingOncologyPharmaceuticalRoche

New treatment avenue identified for breast cancer


Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have…


Indian-Danish contract research merger


Following its acquisition of a majority stake in the Danish firm, India-based Ecron Acunova, a full-service…

aCROnordicEcron AcunovaMergers & AcquisitionsPharmaceutical

Shire to buy regenerative medicines firm Advanced BioHealing for $750 million


Ireland-headquartered biopharmaceutical firm Shire (LSE: SHP) - best known for its attention-deficit…

Advanced BioHealingDermagraftMergers & AcquisitionsPharmaceuticalShire

Pfizer files for US and Japanese approval of crizotinib for NSCLC


US drug behemoth Pfizer (NYSE: PFE) says that its New Drug Application for crizotinib, an oral first-in-class…

Asia-PacificcrizotinibNorth AmericaOncologyPfizerPharmaceuticalRegulation

Turkish pharma - pushed to the limit - calling off some investments


Times are hard for pharmaceutical companies in Turkey, particularly research-based ones, who are left…

EuropeFinancialMarkets & MarketingPharmaceuticalPricing

Dr Reddy’s gains Indian rights to Oceana’s Deflux


Privately-held US company Oceana Therapeutics, which is focused on acquiring, developing and commercializing…

DefluxDr Reddy's LaboratoriesLicensingOceana TherapeuticsPharmaceutical

Australia’s TGA approves Biogen’s Fampyra to improve MS patients walking ability


The Australian Therapeutic Goods Administration (TGA) has granted approval for USA-based Biogen Idec’s…

AmpyraAsia-PacificBiogen IdecFampyraNeurologicalPharmaceuticalRegulation

6651 to 6675 of 6816 results

Back to top